^
Association details:
| Biomarker: | BRCA wild-type |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Zejula (niraparib) (PARP inhibitor) + DAN-222 (Topoisomerase I inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Results from a first-in-human study of DAN-222, a novel high-capacity drug conjugate in metastatic breast cancer as monotherapy and in combination with a PARPi
Published date:
12/02/2023
Excerpt:
A phase 1 study of DAN-222 as monotherapy and in combination with niraparib is being conducted...Clinical activity during dose escalation was demonstrated with stable disease in 28% of patients with monotherapy and 67% of patients with combination therapy across all dose levels...The reduced myelotoxicity of DAN-222 will also enable combination with other therapies to treat patients with other types of cancer. The promising antitumor activity seen with DAN-222 in combination with PARPi in BRCAwt, supports continued clinical development.
Trial ID:
